Home › Calculator › IVBXF Dividend Calculator 2026
IVBXF Dividend DRIP Calculator 2026
20.04% YieldHealthcareInnovent Biologics, Inc. · OTC
Price: $9.98 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When IVBXF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your IVBXF snowball 📈
$10,000 in IVBXF → $12.43M in 10 years · $202.64/month
About Innovent Biologics, Inc. (IVBXF) — Dividend Analysis 2026
Innovent Biologics, Inc. is a biopharmaceutical firm headquartered in Suzhou, People's Republic of China, established in 2011. It specializes in the discovery, advancement, and production of antibody-based drug candidates, with a strategic focus on therapeutic areas including cancer treatment (oncology), eye conditions (ophthalmology), immune system disorders (immunology), and metabolic ailments. Innovent's flagship therapeutic offering is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in managing various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Additionally, its portfolio includes several other approved treatments: Byvasda, for diverse malignant tumors; Halpryza, addressing non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with advanced or metastatic cholangiocarcinoma; Olverembatinib, developed for adult patients requiring tyrosine kinase inhibitor treatment; and Cyramza, which targets four distinct cancer types. Beyond its commercialized products, Innovent maintains a robust pipeline of investigational therapies. These include IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody designed to combat hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody being explored for liver cancer and renal cell carcinoma. The company is also advancing IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy targeting relapsed or refractory multiple myeloma in adults; IBI-376, for recurrent or refractory follicular lymphoma; and IBI-112, designated for psoriasis. Moreover, Innovent provides pharmaceutical product distribution services, alongside offering expert consultation and engaging in research and development activities. Its operational strategy is further bolstered by strategic alliances with partners such as NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
Compare IVBXF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full IVBXF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open IVBXF position with:
🌍 IVBXF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold IVBXF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 20.04% | 17.24% | $2,004 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 17.03% | 14.23% | $1,703 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 16.03% | 13.23% | $1,603 / yr |
| 🇬🇧 UK ISA | 0% | 20.04% | 17.24% | $2,004 / yr |
| 🇬🇧 UK Taxable | 8.75% | 18.29% | 15.49% | $1,829 / yr |
| 🇨🇦 TFSA | 0% | 20.04% | 17.24% | $2,004 / yr |
| 🇨🇦 CA Taxable | 25% | 15.03% | 12.23% | $1,503 / yr |
| 🇦🇺 Super (pension) | 15% | 17.03% | 14.23% | $1,703 / yr |
| 🇦🇺 AU Taxable | 30% | 14.03% | 11.23% | $1,403 / yr |
| 🇩🇪 DE Taxable | 26.375% | 14.75% | 11.95% | $1,475 / yr |
| 🇫🇷 FR Taxable | 30% | 14.03% | 11.23% | $1,403 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 IVBXF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 IVBXF Dividend Payment Schedule
IVBXF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 IVBXF vs Healthcare Benchmarks
How IVBXF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for IVBXF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ IVBXF Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the IVBXF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Innovent Biologics, Inc. (IVBXF) is currently trading at $9.98, 24% below its 52-week high. The current dividend yield is 20.04% based on an annual payout of $2.00 per share.
IVBXF (Innovent Biologics, Inc.) — 20.04% Dividend Yield Analysis
Innovent Biologics, Inc. (IVBXF) is a healthcare stock currently trading at $9.98 with a dividend yield of 20.04%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (20.04%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.